journal cover

CUE-101, a Novel HPV16 E7-pHLA-IL-2-Fc Fusion Protein, Enhances Tumor Antigen Specific T Cell Activation for the Treatment of HPV16-Driven Malignancies

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research

Jan 23, 2020

Steven N QuayleMary Ellen Simcox

Abstract

To assess the potential for CUE-101, a novel therapeutic fusion protein, to selectively activate and expand HPV16 E711-20-specific CD8+T cells as an off-the shelf therapy for the treatment of HPV16-driven tumors, including head and neck squamous cell carcinoma (HNSCC), cervical and anal...read more

Mentioned in this Paper

Peripheral Blood
Histocompatibility Antigens Class I
Antineoplastic Agents
Interleukin-2
Malignant Neoplasms
In Vivo
Mice, Transgenic
Mononucleated Blood Cell
Phase I Clinical Trials
Binding (Molecular Function)
2
10
Paper Details
References
  • References
  • Citations
  • finger pointing at paper

    References currently unavailable

    We're still populating references for this paper, please check back later.
  • References
  • Citations
  • quote and clock

    No citations available

    This paper may not have been cited yet.

Similar Papers Found In These Feeds

Cancer Genomics

Cancer genomics employ high-throughput technologies to identify the complete catalog of somatic alterations that characterize the genome, transcriptome and epigenome of cohorts of tumor samples. Discover the latest research here.

Cancer Genomics (Keystone)

Cancer genomics approaches employ high-throughput technologies to identify the complete catalog of somatic alterations that characterize the genome, transcriptome and epigenome of cohorts of tumor samples. Discover the latest research using such technologies in this feed.

T cell Activation

T cell activation is a crucial checkpoint in adaptive immunity, and this activation depends on the binding parameters that govern the interactions between T cell receptors and peptide-MHC complexes. Here is the latest research.

Killing Mechanisms

Cytolytic t lymphocytes exert two main specific molecular killing mechanisms against target cells, namely (i) they can synthesize and release soluble cytolytic factors, and (ii) they can express effector molecules that act as ligands of receptors expressed by target cells on the cell surface. Here is the latest research on killing mechanisms.

Carcinoma, Squamous Cell

Basal cell carcinoma is a form of malignant skin cancer found on the head and neck regions and has low rates of metastasis. Discover the latest research on basal cell carcinoma here.

Killer Cells

Natural killer cells express inhibitory receptors specific for mhc class i proteins and stimulatory receptors with diverse specificities. Here is the latest research on natural killer cells.

Cross-Priming

Cross-priming is the process whereby professional APC, mainly dendritic cells, prime t-cells by presenting antigens processed from proteins of other cells such as tumor cells or virus-infected cells. Discover the latest research on cross-priming here.

Head & Neck Squamous Cell Carcinoma

Head and neck squamous cell carcinoma (HNSCC) is a malignancy arising in the epithelia of the nasal cavity, pharynx, oral cavity, throat, larynx, or associated structures. Find the latest research on HNSCC here.

Related Papers

Hua xi kou qiang yi xue za zhi = Huaxi kouqiang yixue zazhi = West China journal of stomatology

IL-2 gene and cisplatin combined therapy for head and neck squamous cell carcinoma

Hua xi kou qiang yi xue za zhi = Huaxi kouqiang yixue zazhi = West China journal of stomatologyJanuary 24, 2003
S LiuC Liang
Zhonghua zhong liu za zhi [Chinese journal of oncology]

Combined IL-2 and IL-12 gene therapy for murine head and neck squamous cell carcinoma

Zhonghua zhong liu za zhi [Chinese journal of oncology]November 1, 2002
Shixi LiuC Liang
© 2020 Meta ULC. All rights reserved

CUE-101, a Novel HPV16 E7-pHLA-IL-2-Fc Fusion Protein, Enhances Tumor Antigen Specific T Cell Activation for the Treatment of HPV16-Driven Malignancies

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research

Jan 23, 2020

Steven N QuayleMary Ellen Simcox

PMID: 31964784

DOI: 10.1158/1078-0432.ccr-19-3354

Abstract

To assess the potential for CUE-101, a novel therapeutic fusion protein, to selectively activate and expand HPV16 E711-20-specific CD8+T cells as an off-the shelf therapy for the treatment of HPV16-driven tumors, including head and neck squamous cell carcinoma (HNSCC), cervical and anal...read more

Mentioned in this Paper

Peripheral Blood
Histocompatibility Antigens Class I
Antineoplastic Agents
Interleukin-2
Malignant Neoplasms
In Vivo
Mice, Transgenic
Mononucleated Blood Cell
Phase I Clinical Trials
Binding (Molecular Function)
2
10

Similar Papers Found In These Feeds

Cancer Genomics

Cancer genomics employ high-throughput technologies to identify the complete catalog of somatic alterations that characterize the genome, transcriptome and epigenome of cohorts of tumor samples. Discover the latest research here.

Related Papers

Hua xi kou qiang yi xue za zhi = Huaxi kouqiang yixue zazhi = West China journal of stomatology

IL-2 gene and cisplatin combined therapy for head and neck squamous cell carcinoma

Hua xi kou qiang yi xue za zhi = Huaxi kouqiang yixue zazhi = West China journal of stomatologyJanuary 24, 2003
S LiuC Liang
Zhonghua zhong liu za zhi [Chinese journal of oncology]

Combined IL-2 and IL-12 gene therapy for murine head and neck squamous cell carcinoma

Zhonghua zhong liu za zhi [Chinese journal of oncology]November 1, 2002
Shixi LiuC Liang
Paper Details
References
  • References
  • Citations
  • finger pointing at paper

    References currently unavailable

    We're still populating references for this paper, please check back later.
  • References
  • Citations
  • quote and clock

    No citations available

    This paper may not have been cited yet.
/papers/cue-101-a-novel-hpv16-e7-phla-il-2-fc-fusion/31964784